Immuron (ASX:IMC) recorded a 13% quarterly increase in the global sales of its immune supplement, Travelan, in the September quarter, according to a Tuesday filing with the Australian bourse.
Sales of Travelan in Australia increased 3% to AU$1 million in the September quarter from AU$983,000 in the three months to June. North American sales climbed 48% to AU$456,000 from AU$309,000 in the June quarter.
The biopharmaceutical company's shares were up nearly 4% in recent Tuesday trade.
Price (AUD): $0.09, Change: $+0.003, Percent Change: +3.66%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.